Ablynx
Development of Nanobodies, proprietary therapeutic proteins.
Launch date
Employees
Market cap
-
Enterprise valuation
€3.9b (Public information from Jan 2018)
Company register number 0475.295.446
Ghent East Flanders (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 100m | 200m | 200m | 200m | 200m | 200m |
| % growth | - | 100 % | - | - | - | - |
| EBITDA | - | 100m | 60.0m | 40.0m | 70.0m | 80.0m |
| % EBITDA margin | - | 50 % | 30 % | 20 % | 35 % | 40 % |
| R&D budget | - | - | 33.0m | - | - | - |
| R&D % of revenue | - | - | 17 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€5.0m | Series A | ||
€25.0m | Series B | ||
$50.0m | Series C | ||
| N/A | N/A | IPO | |
| N/A | $31.5m | Post IPO Equity | |
| N/A | €41.7m | Post IPO Equity | |
| N/A | $83.0m | Post IPO Equity | |
| N/A | $82.8m | Post IPO Equity | |
* | N/A | $150m | Post IPO Equity |
* | €3.9b Valuation: €3.9b 19.5x EV/LTM Revenues 65.0x EV/LTM EBITDA | Acquisition | |
| Total Funding | €75.5m | ||
Recent News about Ablynx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.